- guest speakers included a World Health Organization expert on E. coli -
BELLEVILLE, ON, June 27 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, hosted a two-day conference in Toronto this week entitled, "E. coli O157 Vaccine: Added Value or Added Cost". The audience included veterinarians and representatives from the food industry: Beef, dairy, and other agricultural commodity producers.
Guest speakers included Dr. David Biesenthal, a veterinarian in Walkerton, Ontario whose cattle farm was one of those implicated in the town's water contamination with E. coli O157:H7 in 2000. Dr. Biesenthal is one of the first adopters of a vaccination program using the Bioniche E. coli O157:H7 cattle vaccine. "Vaccination of all cattle could help reduce the opportunity for another incident like the one that occurred in Walkerton and would demonstrate due diligence," he said.
Kevin Grier, Senior Market Analyst with the George Morris Centre in Guelph, Ontario presented data from an economic cost-benefit analysis completed for Bioniche related to the vaccine. The analysis concluded that there is a potential $2 saved for every $1 spent on vaccination of the Canadian cattle herd. An executive summary of the report is available on the website http://www.fightecoli.com.
Dr. John Fairbrother, Director of the Reference Laboratory for Escherichia coli (E. coli) at the University of Montreal discussed a variety of potential intervention strategies to address on-farm contamination with E. coli. He concluded that an optimal strategy is a global approach, using combined intervention strategies to improve food safety. Dr. Fairbrother was named as World Health Organization expert on E. coli in 2006.
Dr. David Smith, Professor and Extension Dairy/Beef Veterinarian in the
Department of Veterinary and Biomedical Scienc
|SOURCE Bioniche Life Sciences Inc.|
Copyright©2008 PR Newswire.
All rights reserved